tiprankstipranks
Theralase’s RuvidarTM Shows Multi-Virus Inactivation Potential
Company Announcements

Theralase’s RuvidarTM Shows Multi-Virus Inactivation Potential

Theralase Technologies (TSE:TLT) has released an update.

Don't Miss Our Christmas Offers:

Theralase Technologies Inc. has announced that their lead compound, RuvidarTM, shows promise in inactivating various viruses, including the potential to be used as a broad-spectrum viral vaccine. Research indicates RuvidarTM is highly potent, even at low concentrations, and maintains the integrity of the coronavirus spike protein, suggesting vaccine applications. The company aims to further develop RuvidarTM as an antiviral platform and a topical therapeutic for herpes virus lesions.

For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskTheralase Expands US Bladder Cancer Study Sites
TipRanks Canadian Auto-Generated NewsdeskTheralase Expands Clinical Trial for Bladder Cancer
TipRanks Canadian Auto-Generated NewsdeskTheralase Expands Cancer Study with Promising Results
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App